Pharmaceutical Raw Materials Sex Enhancement Series Avanafil for Muscle Gain 330784-47-9

Pharmaceutical Raw Materials Sex Enhancement Series Avanafil for Muscle Gain 330784-47-9

Abstracto

CASO:330784-47-9
MF:C23H26ClN7O3
MW:483.95
Punto de fusion:150-152° C
Densidad 1.372
temperatura de almacenamiento. Refrigerator
Uso: Used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor.
Store: Store at room temperature away from moisture, calor, and light

Descripción:

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is known by the trademark names and Spedra and was developed by Vivus Inc. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30-45 minutos. About two-thirds of the participants were able to engage in sexual activity within 15 minutes..

Aplicaciones:

Avanafil is used to treat erectile dysfunction (ED: impotence; inability to get or keep an erection in men). Avanafil is in a class of medications called phosphodiesterase (PDE) inhibitors. It works by increasing blood flow to the penis during sexual stimulation. This increased blood flow can cause an erection. Avanafil does not cure erectile dysfunction or increase sexual desire. Avanafil does not prevent pregnancy or the spread of sexually transmitted diseases such as human immunodeficiency virus (HIV).

COA :